Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Interest Coverage Ratio (2016 - 2025)

Historic Interest Coverage Ratio for Protalix BioTherapeutics (PLX) over the last 13 years, with Q1 2025 value amounting to 690.83.

  • Protalix BioTherapeutics' Interest Coverage Ratio fell 544829.08% to 690.83 in Q1 2025 from the same period last year, while for Sep 2025 it was 135.47, marking a year-over-year increase of 284221.35%. This contributed to the annual value of 3.69 for FY2024, which is 1213.07% up from last year.
  • Per Protalix BioTherapeutics' latest filing, its Interest Coverage Ratio stood at 690.83 for Q1 2025, which was down 544829.08% from 175.83 recorded in Q4 2024.
  • Over the past 5 years, Protalix BioTherapeutics' Interest Coverage Ratio peaked at 175.83 during Q4 2024, and registered a low of 690.83 during Q1 2025.
  • Over the past 5 years, Protalix BioTherapeutics' median Interest Coverage Ratio value was 4.1 (recorded in 2023), while the average stood at 32.45.
  • Its Interest Coverage Ratio has fluctuated over the past 5 years, first surged by 252371.96% in 2024, then tumbled by 544829.08% in 2025.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Interest Coverage Ratio stood at 6.28 in 2021, then skyrocketed by 38.92% to 3.84 in 2022, then plummeted by 89.0% to 7.25 in 2023, then soared by 2523.72% to 175.83 in 2024, then crashed by 492.9% to 690.83 in 2025.
  • Its Interest Coverage Ratio stands at 690.83 for Q1 2025, versus 175.83 for Q4 2024 and 15.35 for Q3 2024.